ChromaDex Earnings Conference Call Fourth Quarter 2020 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | March 10, 2021 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 26-2940963 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share CDXC The Nasdaq Capital Market Large accelerated filer ☐ Non-accelerated filer ☒ Accelerated filer ☐ Smaller reporting company ☒ Emerging growth company ☐ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH ...

Financial Data and Key Metrics Changes - Total company sales grew 9% sequentially and 18% year-over-year, with total net sales nearly $60 million and Tru Niagen net sales at $47 million for the year [10][27] - Adjusted EBITDA for Q4 2020 was a loss of $1.1 million, improving by $1 million year-over-year, with a full-year loss of $1 million compared to $8.8 million in 2019 [11][41] - Gross margins increased to 61%, up approximately 400 basis points year-over-year [28][39] Business Line Data and Key Metrics Changes - Tru Niagen net sales grew 31% year-over-year, with e-commerce sales up 20% [27][38] - Niagen ingredient sales more than doubled in Q4 to $2.2 million compared to $0.9 million in the previous quarter [32] Market Data and Key Metrics Changes - Tru Niagen will soon be available in 3,000 Walmart stores across the U.S., expanding the distribution footprint significantly [14] - The company has established partnerships with major players like A.S. Watson Group and Nestlé Health Science, enhancing market presence [13] Company Strategy and Development Direction - The company aims to achieve cash flow break-even while expanding scientific research on Niagen and increasing marketing investments [11][17] - Focus on building a global brand and exploring new retail partnerships while maintaining a careful and selective approach to collaborations [83] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting strong scientific research and a growing body of evidence supporting Niagen's health benefits [12][26] - The addressable market for Niagen is large, with increasing consumer awareness and a commitment to long-term value creation [17][29] Other Important Information - The company ended the year with $16.7 million in cash and raised an additional $25 million in February 2021 [29][42] - Significant investments in R&D are planned to develop new formulations and delivery mechanisms for existing products [68][69] Q&A Session Summary Question: Details on Walmart partnership and stocking - The company plans to offer a lower dose and price point for Walmart, with a focus on creating awareness through marketing [47] Question: COVID-19 trial in Turkey - Management discussed ongoing studies related to COVID-19 and the potential of Tru Niagen, noting the differences in standard of care between Turkey and the U.S. [50][51] Question: Changes in marketing strategy for 2021 - The company will continue using influencers while targeting different customer cohorts with tailored marketing channels [65][66] Question: Future retail partnerships - While there are no immediate plans for additional retail partnerships, the company remains open to opportunities that align with its strategic goals [83]

Investor Presentation Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer TRU NIAGEN® Nasdaq: CDXC | December 2020 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements reflect the current view about future events. Sta ...

ChromaDex Corporation (NASDAQ:CDXC) Q3 2020 Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Brianna Gerber – Vice President-FP&A and Investor Relations Rob Fried – Chief Executive Officer Frank Jaksch – Co-Founder and Executive Chairman Kevin Farr – Chief Financial Officer Conference Call Participants Jeffrey Cohen – Ladenburg Brian Nagel – Oppenheimer Jeff Van Sinderen – B. Riley FBR Ram Selvaraju – H.C. Wainwright Mitchell Pinheiro – Sturdivant & Company JP Mark – Farmhouse Equit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State incorporation or (I.R.S. Employer Identification No.) orotherjurisdictionof organization) 10900 Wilshire Blvd. Suite 600, Los Angeles, CA (Address of Pr ...

ChromaDex Corporation (NASDAQ:CDXC) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Brianna Gerber - Vice President, FP&A & Investor Relations Rob Fried - Chief Executive Officer Frank Jaksch - Founder & Executive Chairman Kevin Farr - Chief Financial Officer Conference Call Participants Jeff Vansen Sinderen - B. Riley Brian Nagel - Oppenheimer Mitchell Pinheiro - Sturdivant JP Mark - Farmhouse Equity Research Matt Dhane - Tieton Capital Management Operator Ladies and gentlem ...

ChromaDex Earnings Conference Call Second Quarter 2020 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | August 6, 2020 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | |-------------|--------------------------------------------------------------| | | Delaware | | (State or | other jurisdiction of incorporation or organization) | 26-2940 ...

Investor Presentation Rob Fried Chief Executive Officer Kevin Farr Chief Financial Officer TRU NIAGEN Nasdaq: CDXC | June 2020 1 SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements reflect the current view about future events. Statemen ...